You are viewing an incomplete version of our website. Please click to reload the website as full version.

anti-BRCA2 (BRCA2) 抗体产品概述

Full name:
anti-Breast Cancer 2, Early Onset 抗体 (BRCA2)
在www.antibodies-online.cn可供87 Breast Cancer 2, Early Onset (BRCA2) 抗体的22不同的供货商。 再加上,我们可以发BRCA2 试剂盒 (24)BRCA2 蛋白 (2)和数多这个蛋白质的别的产品。 总共116 BRCA2产品已列进来了。
别名:
AI256696, AW045498, BRCA2, BRCC2, BROVCA2, FACD, FAD, FAD1, FANCB, FANCD, FANCD1, GLM3, PNCA2, RAB163
列出全部抗体 基因 基因ID UniProt
BRCA2 12190 P97929
BRCA2 675 P51587
BRCA2 360254  

显示所有的来源

显示所有的同义词

最受欢迎的抗anti-BRCA2 (BRCA2) 抗体

选择您的来源和应用

抗Mouse (Murine) BRCA2 抗体:

抗Human BRCA2 抗体:

抗Rat (Rattus) BRCA2 抗体:

所有可销售的anti-BRCA2 抗体

您会转到已过滤好的搜索

引用最多的anti-BRCA2 抗体

  1. Human Monoclonal BRCA2 Primary Antibody for IHC, IHC (p) - ABIN445491 : Wu, Jiang, Thangaraju, Wu, Couch: Induction of the BRCA2 promoter by nuclear factor-kappa B. in The Journal of biological chemistry 2000 (PubMed)
    Show all 2 references for ABIN445491

  2. Human Monoclonal BRCA2 Primary Antibody for IHC, IHC (fro) - ABIN445493 : Bernard-Gallon, Déchelotte, Vissac, Aunoble, Cravello, Malpuech, Bignon: BRCA1 and BRCA2 protein expressions in an ovotestis of a 46, XX true hermaphrodite. in Breast cancer research : BCR 2001 (PubMed)
    Show all 2 references for ABIN445493

  3. Human Polyclonal BRCA2 Primary Antibody for IHC, ELISA - ABIN1533759 : Wooster, Bignell, Lancaster, Swift, Seal, Mangion, Collins, Gregory, Gumbs, Micklem: Identification of the breast cancer susceptibility gene BRCA2. in Nature 1996 (PubMed)
    Show all 2 references for ABIN1533759

  4. Human Polyclonal BRCA2 Primary Antibody for IHC, IHC (fro) - ABIN4285196 : Moeller, Yordy, Williams, Giri, Raju, Molkentine, Byers, Heymach, Story, Lee, Sturgis, Weber, Garden, Ang, Schwartz: DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy. in Clinical cancer research : an official journal of the American Association for Cancer Research 2011 (PubMed)

更多抗BRCA2的相互作用对抗体

Zebrafish Breast Cancer 2, Early Onset (BRCA2) interaction partners

  1. Carcinogenesis in zebrafish with combined mutations in tp53 (显示 TP53 抗体) and brca2 typically requires biallelic mutation or loss of at least one of these genes.

  2. The novel role of Brca2 in organizing the vertebrate egg nucleus may provide new insights into the origin of ovarian cancer

  3. critical roles for brca2 in ovarian development and tumorigenesis in reproductive tissues

Mouse (Murine) Breast Cancer 2, Early Onset (BRCA2) interaction partners

  1. we describe a genetic approach to examine the functional significance of the interaction between BRCA2 and PALB2 (显示 PALB2 抗体) by generating a knock-in mouse model of Brca2 carrying a single amino acid change (Gly25Arg, Brca2G25R) that disrupts this interaction. In addition, we have combined Brca2G25R homozygosity as well as hemizygosity with Palb2 (显示 PALB2 抗体) and Trp53 (显示 TP53 抗体) heterozygosity .

  2. Merit40 (显示 BABAM1 抗体) mutation exacerbated ICL-induced chromosome instability in the context of concomitant Brca2 deficiency but not in conjunction with Fancd2 (显示 FANCD2 抗体) mutation.

  3. Heterozygous and homozygous Brca2 mutation may lead to dysfunction in T cell populations.

  4. BRCA2 exon 27 domain maintains chromosomal integrity at both stalled and collapsed replication forks consistent with involvement in both replication fork maintenance and double strand break repair.

  5. we use a genetically engineered mouse model of BRCA2-associated hereditary breast cancer to study drug resistance to several types of chemotherapy and PARP (显示 PARP1 抗体) inhibition.

  6. BRCA2-mediated sequestration of nuclear RAD51 (显示 RAD51 抗体) serves to prevent inappropriate DNA interactions.

  7. BRCA2 directly represses the expression of IFN-related genes

  8. the models reveal novel aspects of cancer evolution in carriers of germline BRCA2 mutations, provide new insights into the tumour suppressive role of BRCA2

  9. genetic stability, and hematopoietic differentiation potential of gene-corrected Brca2(Delta) (27/) (Delta) (27) iPSCs, achievements and limitations in the application of current reprogramming approaches in hematopoietic stem cell therapy are also discussed.

  10. Results suggest that cellular levels of Brca2 and Rad51 (显示 RAD51 抗体) are mutually dependent on each other, and that low levels of these proteins provide selective pressure for reduction of p53 (显示 TP53 抗体), which permits cell growth

Human Breast Cancer 2, Early Onset (BRCA2) interaction partners

  1. Our aim was to set up a cost-effective and low time-consuming BRCA1-BRCA2 mutation detection workflow using the Ion Torrent PGM (显示 Vcan 抗体) technology. A retrospective cohort of 40 patients with familial breast/ovarian cancer previously tested by Sanger sequencing and a prospective cohort of 72 patients (validation set) were analyzed.

  2. This is the largest study in Cyprus evaluating the prevalence and spectrum of BRCA1/2 mutations. Thirteen percent of the patients tested were positive for deleterious mutations which are within the range reported in other countries

  3. ubiquitination of RAD51 (显示 RAD51 抗体) hinders RAD51 (显示 RAD51 抗体)-BRCA2 interaction, while deubiquitination of RAD51 (显示 RAD51 抗体) facilitates RAD51 (显示 RAD51 抗体)-BRCA2 binding and RAD51 (显示 RAD51 抗体) recruitment and thus is critical for proper homologous recombination

  4. We studied effect of food on ABT-767 bioavailability in subjects with advanced BRCA1 or BRCA2 mutated solid tumors or high grade serous ovarian, primary peritoneal or fallopian tube cancer

  5. These results suggest that cytoplasmic dynein (显示 DYNC1H1 抗体) 1 binds to BRCA2 through the latter's centrosomal localization signal and BRCA2 mediates the cohesion between centrosomes during the S phase, potentially serving as a cell-cycle checkpoint.

  6. Results indicate that aberrant splicing is especially prevalent in breast cancer 2 protein (BRCA2) exons 17 and 18.

  7. BRCA2 mutation carriers are at increased risk developing insulin (显示 INS 抗体) resistance and type-II diabetes mellitus; have an altered expression of circulating proteins associated with venous thrombo-embolism (Review)

  8. BRCA2 reversion mutation is associated with resistance to PARP (显示 COL11A2 抗体) inhibitor-based therapy in a pancreatic ductal adenocarcinoma.

  9. BRCA1/2-associated EOC patients with a previous BC have a worse outcome.

  10. By monitoring DNA double-strand breaks mis (显示 AMH 抗体)-repair using a sensitive bioassay, it was found that depletion of homologous recombination proteins, including BRCA2, BRCA1 or RPA1 (显示 RPA1 抗体), resulted in a distinct mutational signature associated with significant increases in break-induced mutation frequencies.

BRCA2 抗原简介

Antigen Summary

Inherited mutations in BRCA1 and this gene, BRCA2, confer increased lifetime risk of developing breast or ovarian cancer. Both BRCA1 and BRCA2 are involved in maintenance of genome stability, specifically the homologous recombination pathway for double-strand DNA repair. The BRCA2 protein contains several copies of a 70 aa motif called the BRC motif, and these motifs mediate binding to the RAD51 recombinase which functions in DNA repair. BRCA2 is considered a tumor suppressor gene, as tumors with BRCA2 mutations generally exhibit loss of heterozygosity (LOH) of the wild-type allele.

Alternative names and synonyms associated with BRCA2

  • breast cancer 2, early onset (BRCA2) 抗体
  • breast cancer 2, early onset (brca2) 抗体
  • breast cancer 2 (Brca2) 抗体
  • breast cancer 2, early onset (Brca2) 抗体
  • AI256696 抗体
  • AW045498 抗体
  • BRCA2 抗体
  • BRCC2 抗体
  • BROVCA2 抗体
  • FACD 抗体
  • FAD 抗体
  • FAD1 抗体
  • FANCB 抗体
  • FANCD 抗体
  • FANCD1 抗体
  • GLM3 抗体
  • PNCA2 抗体
  • RAB163 抗体

Protein level used designations for BRCA2

breast and ovarian cancer susceptibility protein 2 , breast cancer 2, early onset , breast cancer type 2 susceptibility protein-like , breast cancer type 2 susceptibility protein homolog , fanconi anemia group D1 protein homolog , BRCA1/BRCA2-containing complex, subunit 2 , breast and ovarian cancer susceptibility gene, early onset , breast cancer 2 tumor suppressor , breast cancer type 2 susceptibility protein , fanconi anemia group D1 protein , truncated breast and ovarian cancer susceptibility protein 2 , breast cancer 2, mutation 1, University of Wisconsin-Madison , breast cancer susceptibility protein 2

GENE ID SPECIES
100064578 Equus caballus
566758 Danio rerio
584780 Strongylocentrotus purpuratus
721981 Macaca mulatta
100397509 Callithrix jacchus
452526 Pan troglodytes
100038818 Xenopus (Silurana) tropicalis
100601625 Nomascus leucogenys
12190 Mus musculus
675 Homo sapiens
360254 Rattus norvegicus
374139 Gallus gallus
474180 Canis lupus familiaris
507069 Bos taurus
493878 Felis catus
anti-BRCA2 (BRCA2) 抗体 精选生产商
您还需要查找其他产品吗?